Somewhat Favorable Media Coverage Somewhat Unlikely to Affect Organovo (ONVO) Stock Price
Media coverage about Organovo (NASDAQ:ONVO) has been trending somewhat positive on Sunday, Accern Sentiment reports. The research group identifies negative and positive media coverage by monitoring more than 20 million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Organovo earned a media sentiment score of 0.11 on Accern’s scale. Accern also gave media coverage about the medical research company an impact score of 45.9172081412027 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.
Here are some of the news headlines that may have impacted Accern’s analysis:
- Organovo (ONVO) Announces Earnings Results (americanbankingnews.com)
- Organovo Holdings Q1 revenues down 30% (seekingalpha.com)
- Organovo Holdings, Inc. (ONVO) CEO Taylor Crouch on Q1 2019 Results – Earnings Call Transcript (seekingalpha.com)
- Organovo reports smaller loss and sharp fall in revenue (proactiveinvestors.com)
- Organovo: Fiscal 1Q Earnings Snapshot (finance.yahoo.com)
Several research firms recently issued reports on ONVO. Jefferies Financial Group reissued a “buy” rating and set a $1.75 target price on shares of Organovo in a research note on Friday, July 27th. Zacks Investment Research lowered Organovo from a “buy” rating to a “hold” rating in a research note on Saturday, June 2nd. Finally, ValuEngine raised Organovo from a “sell” rating to a “hold” rating in a research note on Saturday, June 2nd. Four investment analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. The stock presently has an average rating of “Hold” and an average target price of $2.75.
Organovo (NASDAQ:ONVO) last posted its quarterly earnings results on Thursday, August 9th. The medical research company reported ($0.07) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.07). The company had revenue of $0.69 million for the quarter, compared to analyst estimates of $1.16 million. Organovo had a negative return on equity of 66.34% and a negative net margin of 746.56%. equities analysts anticipate that Organovo will post -0.27 earnings per share for the current fiscal year.
Organovo Holdings, Inc, a biotechnology company, provides therapeutic and drug profiling capabilities based on its 3D bioprint tissues that emulate human biology and diseases. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture.
Featured Article: Diversification in Investing
Receive News & Ratings for Organovo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Organovo and related companies with MarketBeat.com's FREE daily email newsletter.